Theravance Biopharma (TBPH)
Commercializes YUPELRI with Viatris while winding down ampreloxetine.
$17.08
At close+0.05 (+0.29%)
Something off on this page? Send us feedback.
Next report
Nov 10, 2026
in 68 days
EPS estimate
$0.24
Revenue estimate
$22.0M
Fiscal quarter
Q3 FY26
EPSReportedEstimate
May '25Aug '25Nov '25Mar '26May '26Aug '26Aug '26Nov '26
Reported−$0.17−$0.08$0.04$0.06−$0.10−$0.11−$0.11Pending
Estimate−$0.11−$0.14−$0.03$0.44$0.03$0.07$0.07$0.24
Surprise−54.5%+42.9%+233.3%−86.4%−443.6%−251.7%−251.7%—
RevenueReportedEstimate
May '25Aug '25Nov '25Mar '26May '26Aug '26Aug '26Nov '26
Reported$15.4M$26.2M$20.0M$45.9M$17.7M$20.7M$20.7MPending
Estimate$16.1M$18.7M$43.1M$56.6M$17.8M$22.5M$22.5M$22.0M
Surprise−4.4%+39.9%−53.6%−18.9%−0.5%−7.8%−7.8%—
History
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | $0.24 | — | — |
| Aug 2026 | $0.07 | −$0.11 | −251.7% |
| Aug 2026 | $0.07 | −$0.11 | −251.7% |
| May 2026 | $0.03 | −$0.10 | −443.6% |
| Mar 2026 | $0.44 | $0.06 | −86.4% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | |||
| Nov 2025 | |||
| Aug 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Feb 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Feb 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Feb 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Feb 2020 | |||
| Nov 2019 | |||
| Jul 2019 | |||
| May 2019 | |||
| Feb 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Feb 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Feb 2017 | |||
| Nov 2016 | |||
| Aug 2016 | |||
| May 2016 | |||
| Mar 2016 | |||
| Nov 2015 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Nov 10, 2026 | $0.24 | — | — | $22.0M | — | — | — |
| Aug 11, 2026 | $0.07 | −$0.11 | −251.7% | $22.5M | $20.7M | −7.8% | +0.1% |
| Aug 10, 2026 | $0.07 | −$0.11 | −251.7% | $22.5M | $20.7M | −7.8% | −0.1% |
| May 7, 2026 | $0.03 | −$0.10 | −443.6% | $17.8M | $17.7M | −0.5% | −0.1% |
| Mar 19, 2026 | $0.44 | $0.06 | −86.4% | $56.6M | $45.9M | −18.9% | +2.3% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | |||||||
| Nov 10, 2025 | |||||||
| Aug 12, 2025 | |||||||
| May 8, 2025 | |||||||
| Feb 26, 2025 | |||||||
| Nov 12, 2024 | |||||||
| Aug 5, 2024 | |||||||
| May 13, 2024 | |||||||
| Feb 26, 2024 | |||||||
| Nov 7, 2023 | |||||||
| Aug 7, 2023 | |||||||
| May 8, 2023 | |||||||
| Feb 27, 2023 | |||||||
| Nov 7, 2022 | |||||||
| Aug 4, 2022 | |||||||
| May 5, 2022 | |||||||
| Feb 23, 2022 | |||||||
| Nov 3, 2021 | |||||||
| Aug 3, 2021 | |||||||
| May 4, 2021 | |||||||
| Feb 23, 2021 | |||||||
| Nov 5, 2020 | |||||||
| Aug 6, 2020 | |||||||
| May 6, 2020 | |||||||
| Feb 24, 2020 | |||||||
| Nov 5, 2019 | |||||||
| Jul 31, 2019 | |||||||
| May 7, 2019 | |||||||
| Feb 26, 2019 | |||||||
| Nov 6, 2018 | |||||||
| Aug 1, 2018 | |||||||
| May 8, 2018 | |||||||
| Feb 27, 2018 | |||||||
| Nov 7, 2017 | |||||||
| Aug 8, 2017 | |||||||
| May 9, 2017 | |||||||
| Feb 27, 2017 | |||||||
| Nov 8, 2016 | |||||||
| Aug 8, 2016 | |||||||
| May 9, 2016 | |||||||
| Mar 9, 2016 | |||||||
| Nov 9, 2015 | |||||||